These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25984871)

  • 21. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.
    Anderson JL; Heidenreich PA; Barnett PG; Creager MA; Fonarow GC; Gibbons RJ; Halperin JL; Hlatky MA; Jacobs AK; Mark DB; Masoudi FA; Peterson ED; Shaw LJ
    J Am Coll Cardiol; 2014 Jun; 63(21):2304-22. PubMed ID: 24681044
    [No Abstract]   [Full Text] [Related]  

  • 22. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Estes NA; Kovacs RJ; Baggish AL; Myerburg RJ;
    Circulation; 2015 Dec; 132(22):e330-3. PubMed ID: 26621651
    [No Abstract]   [Full Text] [Related]  

  • 23. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
    Yancy CW; Jessup M; Bozkurt B; Butler J; Casey DE; Drazner MH; Fonarow GC; Geraci SA; Horwich T; Januzzi JL; Johnson MR; Kasper EK; Levy WC; Masoudi FA; McBride PE; McMurray JJ; Mitchell JE; Peterson PN; Riegel B; Sam F; Stevenson LW; Tang WH; Tsai EJ; Wilkoff BL
    Circulation; 2013 Oct; 128(16):1810-52. PubMed ID: 23741057
    [No Abstract]   [Full Text] [Related]  

  • 25. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Zipes DP; Link MS; Ackerman MJ; Kovacs RJ; Myerburg RJ; Estes NA;
    Circulation; 2015 Dec; 132(22):e315-25. PubMed ID: 26621650
    [No Abstract]   [Full Text] [Related]  

  • 26. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Braverman AC; Harris KM; Kovacs RJ; Maron BJ;
    Circulation; 2015 Dec; 132(22):e303-9. PubMed ID: 26621648
    [No Abstract]   [Full Text] [Related]  

  • 27. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
    Yancy CW; Jessup M; Bozkurt B; Butler J; Casey DE; Colvin MM; Drazner MH; Filippatos GS; Fonarow GC; Givertz MM; Hollenberg SM; Lindenfeld J; Masoudi FA; McBride PE; Peterson PN; Stevenson LW; Westlake C
    J Card Fail; 2017 Aug; 23(8):628-651. PubMed ID: 28461259
    [No Abstract]   [Full Text] [Related]  

  • 28. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Mitten MJ; Zipes DP; Maron BJ; Bryant WJ;
    Circulation; 2015 Dec; 132(22):e346-9. PubMed ID: 26621654
    [No Abstract]   [Full Text] [Related]  

  • 29. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13: Commotio Cordis: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Link MS; Estes NA; Maron BJ;
    Circulation; 2015 Dec; 132(22):e339-42. PubMed ID: 26621653
    [No Abstract]   [Full Text] [Related]  

  • 30. 2014 European Society of Cardiology/European Society of Anaesthesiology guidelines on non-cardiac surgery: cardiovascular assessment and management: A short explanatory statement from the European Society of Anaesthesiology members who participated in the European Task Force.
    Longrois D; Hoeft A; De Hert S
    Eur J Anaesthesiol; 2014 Oct; 31(10):513-6. PubMed ID: 26656566
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison Between the 2007 and 2014 American College of Cardiology/American Heart Association Guidelines on Perioperative Evaluation for Noncardiac Surgery.
    Oprea AD; Fontes ML; Onaitis MW; Kertai MD
    J Cardiothorac Vasc Anesth; 2015 Dec; 29(6):1639-50. PubMed ID: 26341877
    [No Abstract]   [Full Text] [Related]  

  • 32. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).
    Kristensen SD; Knuuti J; Saraste A; Anker S; Bøtker HE; De Hert S; Ford I; Gonzalez Juanatey JR; Gorenek B; Heyndrickx GR; Hoeft A; Huber K; Iung B; Kjeldsen KP; Longrois D; Luescher TF; Pierard L; Pocock S; Price S; Roffi M; Sirnes PA; Uva MS; Voudris V; Funck-Brentano C;
    Eur J Anaesthesiol; 2014 Oct; 31(10):517-73. PubMed ID: 25127426
    [No Abstract]   [Full Text] [Related]  

  • 33. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Estes NAM; Kovacs RJ; Baggish AL; Myerburg RJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2429-2433. PubMed ID: 26542661
    [No Abstract]   [Full Text] [Related]  

  • 34. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 12: Emergency Action Plans, Resuscitation, Cardiopulmonary Resuscitation, and Automated External Defibrillators: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Link MS; Myerburg RJ; Estes NA;
    Circulation; 2015 Dec; 132(22):e334-8. PubMed ID: 26621652
    [No Abstract]   [Full Text] [Related]  

  • 35. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Mitten MJ; Zipes DP; Maron BJ; Bryant WJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2447-2450. PubMed ID: 26542663
    [No Abstract]   [Full Text] [Related]  

  • 36. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Levine BD; Baggish AL; Kovacs RJ; Link MS; Maron MS; Mitchell JH
    J Am Coll Cardiol; 2015 Dec; 66(21):2350-2355. PubMed ID: 26542656
    [No Abstract]   [Full Text] [Related]  

  • 37. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Bonow RO; Nishimura RA; Thompson PD; Udelson JE
    J Am Coll Cardiol; 2015 Dec; 66(21):2385-2392. PubMed ID: 26542667
    [No Abstract]   [Full Text] [Related]  

  • 38. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Levine BD; Washington RL; Baggish AL; Kovacs RJ; Maron MS
    J Am Coll Cardiol; 2015 Dec; 66(21):2356-2361. PubMed ID: 26542659
    [No Abstract]   [Full Text] [Related]  

  • 39. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Zipes DP; Kovacs RJ;
    Circulation; 2015 Dec; 132(22):e256-61. PubMed ID: 26621642
    [No Abstract]   [Full Text] [Related]  

  • 40. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Van Hare GF; Ackerman MJ; Evangelista JK; Kovacs RJ; Myerburg RJ; Shafer KM; Warnes CA; Washington RL
    J Am Coll Cardiol; 2015 Dec; 66(21):2372-2384. PubMed ID: 26542660
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.